Prime editing can potentially repair the vast majority of known disease-causing human mutations, but the technology, first developed in 2019, has not yet been widely used in the body, or in vivo, to ...
Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. Dr. David Liu, pictured with former lab members Holly Rees ...
An optimized version of prime editing technology raises the possibility of a one-time treatment for cystic fibrosis. In their 2019 paper, Liu’s team used prime editing to alter the gene mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results